Results 21 to 30 of about 38,006 (217)

165 Rates of SGLT2 Inhibitor Use in Patients With Diabetes and Heart Failure in the Southeastern United States

Journal of Clinical and Translational Science, 2022
OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli, Zihao Liu, Jeffrey Wang, Alexis Okoh, Shivani Patel, Alanna A. Morris   +5 more
doaj   +1 more source

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

Kidney & Blood Pressure Research, 2023
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include ...
Jinfang Song, Xia Li, Jiang Ni
doaj   +1 more source

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns [PDF]

Exploration of Medicine
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management.
Farazul Hoda, Harsha Negi, Digvijaya Saini, Mawrah Arshad, Sidra Zayed, Mukesh Kumar Raut, Mohammad Anwar Habib, Mohd Akhtar, Abul Kalam Najmi   +8 more
doaj   +1 more source

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study

Diabetes & Vascular Disease Research, 2022
Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.
Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong   +4 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

T‐Cell Remodeling in Renal Fibrosis: From Acute Injury to Chronic Kidney Disease

Advanced Science, EarlyView.
This Review presents renal fibrosis as a sequence of overlapping T‐cell programs, from chemokine‐guided recruitment and metabolic activation to maladaptive polarization, tertiary lymphoid structure formation, tissue residency, exhaustion, and senescence.
Qianhui Li, Junting Guan, Yifan Song, Hongxia Yang, Guangtao Li, Xiaodong Zhao, Jiaxin Liu, Bin Liu, Yang Tan, Honglan Zhou, Yang‐He Zhang, Yishu Wang   +11 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease

The Scientific World Journal, 2015
SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli, A. Granata, P. Lentini, S. Rastelli, P. Fatuzzo, F. Rapisarda, P. Castellino   +6 more
doaj   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis

Cardio-Oncology
Background The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on reducing cardiovascular events in different subgroups of diabetic patients are under investigation. The current systematic review and meta-analysis investigated the effects of
Tara Reshadmanesh, Reza Mohebi, Amir Hossein Behnoush, Azadeh Reshadmanesh, Amirmohammad Khalaji, Mitra Norouzi, Elmira Javanmardi, Reza Pishdad, S. Reza Jafarzadeh, Elina Ghondaghsaz, Sandra Chaparro   +10 more
doaj   +1 more source